Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Ovarian Neoplasms 3Mesothelioma, Malignant 3Solid Tumors 2Neoplasm Metastasis 2Disease Progression 2Small Cell Lung Carcinoma 1Sarcoma 1Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Advanced Solid Tumors 1

Interventions

Doxorubicin 33pembrolizumab 16Gemcitabine 15eribulin 10Irinotecan 10olaratumab 9Trabectedin 9pazopanib 8Docetaxel 8Injections 7Cyclophosphamide 7Nivolumab 6Fluorouracil 6anlotinib 5Temozolomide 5Ipilimumab 5Ifosfamide 5Bevacizumab 5tazemetostat 4ridaforolimus 4Drug Therapy 4Cetuximab 4Carboplatin 4toripalimab 3surufatinib 3spartalizumab 3ganitumab 3entrectinib 3conatumumab 3belinostat 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Sarcoma × tumor necrosis factor-alpha, CNGRC fusion protein, human × Clear all
NCT00484341 2018-08-29

Phase II Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Soft Tissue Sarcomas.

AGC Biologics S.p.A.

Phase 2 Completed
69 enrolled
Sarcoma

Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡